23.04

0.30% 0.04

Pacira Biosciences Inc (PCRX)

Overview News Price History Option Chain Financials Discussions Forecast

Pacira Biosciences Inc stock is traded at $23.04, with a volume of 285.52K. It is up +0.30% in the last 24 hours and down -9.92% over the past month. Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Previous Close:

$23.00

Open:

$23.23

24h Volume:

285.52K

Relative Volume:

0.53

Market Cap:

$918.42M

Revenue:

$734.86M

Net Income/Loss:

$5.14M

P/E Ratio:

184.32

EPS:

0.125

Net Cash Flow:

$132.71M

1W Performance:

-5.57%

1M Performance:

-9.92%

6M Performance:

+1.45%

1Y Performance:

-6.90%

1-Day Range:

$22.97

$23.72

1-Week Range:

$22.79

$24.78

52-Week Range:

$18.80

$27.66

Pacira Biosciences Inc Stock (PCRX) Company Profile

Name

Pacira Biosciences Inc

Sector

Healthcare (1089)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

650-242-8052

Address

2000 SIERRA POINT PARKWAY, BRISBANE, NJ

Employee

829

Twitter

Next Earnings Date

2026-08-04

Latest SEC Filings

PCRX's Discussions on Twitter

Compare PCRX vs TAK, TEVA, HLN, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PCRX Pacira Biosciences Inc	23.04	916.82M	734.86M	5.14M	132.71M	0.125
TAK Takeda Pharmaceutical Co Adr	17.36	56.30B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	36.54	42.85B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.58	42.72B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	72.43	30.49B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	506.25	21.43B	3.17B	1.29B	1.01B	27.09

Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-09-25	Initiated	Barclays	Equal Weight
Nov-17-25	Initiated	H.C. Wainwright	Buy
Jul-25-25	Upgrade	Truist	Hold → Buy
Jan-30-25	Upgrade	Truist	Sell → Hold
Aug-13-24	Downgrade	Truist	Buy → Sell
Aug-12-24	Downgrade	JP Morgan	Overweight → Underweight
Aug-12-24	Downgrade	Piper Sandler	Overweight → Neutral
Aug-12-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Aug-12-24	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-03-24	Downgrade	Barclays	Overweight → Equal Weight
Mar-07-24	Resumed	JP Morgan	Overweight
Dec-20-23	Initiated	Raymond James	Outperform
Aug-03-23	Upgrade	TD Cowen	Market Perform → Outperform
Jan-31-23	Resumed	Wedbush	Outperform
Oct-21-22	Resumed	Jefferies	Buy
Jan-03-22	Resumed	JP Morgan	Overweight
Jul-26-21	Upgrade	JP Morgan	Neutral → Overweight
Apr-21-21	Resumed	JP Morgan	Neutral
Apr-09-21	Initiated	Berenberg	Buy
Apr-07-21	Resumed	RBC Capital Mkts	Outperform
Feb-11-21	Downgrade	Northland Capital	Outperform → Market Perform
Jan-21-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Sep-21-20	Upgrade	Northland Capital	Market Perform → Outperform
Jul-06-20	Reiterated	Needham	Buy
May-27-20	Initiated	Guggenheim	Neutral
Apr-07-20	Initiated	Northland Capital	Outperform
Mar-20-20	Upgrade	SVB Leerink	Mkt Perform → Outperform
Feb-24-20	Reiterated	H.C. Wainwright	Buy
Jan-24-20	Initiated	SunTrust	Buy
Jan-23-20	Initiated	SunTrust	Buy
Nov-06-19	Initiated	BTIG Research	Buy
Jun-11-19	Initiated	Barclays	Overweight
May-06-19	Upgrade	Mizuho	Underperform → Neutral
May-02-19	Upgrade	Stifel	Sell → Hold
Feb-01-19	Downgrade	Mizuho	Neutral → Underperform
Aug-06-18	Downgrade	BofA/Merrill	Buy → Neutral
Apr-09-18	Reiterated	H.C. Wainwright	Buy
Mar-21-18	Reiterated	Mizuho	Neutral
Feb-16-18	Downgrade	Needham	Buy → Hold
Jan-19-18	Initiated	Seaport Global Securities	Buy
Jan-04-18	Reiterated	Canaccord Genuity	Buy
Jan-03-18	Initiated	Leerink Partners	Mkt Perform

View All

Pacira Biosciences Inc Stock (PCRX) Latest News

11:54 AM

Pacira BioSciences (NASDAQ: PCRX) faces $70.6K share sale in 2026 - Stock Titan

11:54 AM

10:11 AM

Pacira BioSciences (NASDAQ:PCRX) Coverage Initiated at Truist Financial - marketbeat.com

10:11 AM

06:01 AM

Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Recommendation of "Hold" from Brokerages - marketbeat.com

06:01 AM

03:44 AM

Empowered Funds LLC Buys 49,171 Shares of Pacira BioSciences, Inc. $PCRX - marketbeat.com

03:44 AM

Aug 16, 2026

Pacira BioSciences (NASDAQ:PCRX) Lowered to "Buy" Rating by Wall Street Zen - marketbeat.com

Aug 16, 2026

Aug 14, 2026

Wedge Capital Management L L P NC Purchases New Stake in Pacira BioSciences, Inc. $PCRX - marketbeat.com

Aug 14, 2026

Assenagon Asset Management S.A. Acquires Shares of 101,429 Pacira BioSciences, Inc. $PCRX - marketbeat.com

Aug 14, 2026

Aug 12, 2026

(PCRX) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Aug 12, 2026

Aug 11, 2026

Pacira BioSciences (PCRX) Is Down 7.1% After Advancing PCRX-201 Gene Therapy With Positive Phase 1 Data - Sahm

Aug 11, 2026